Clinical trials: Advanced Small Bowel Adenocarcinoma
Small Bowel Adenocarcinoma
Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
The study regimen will be administered on an outpatient basis and all medications are administered intravenously (IV). Subjects will receive treatment on Day 1 and Day 15 of each 28-day cycle consisting of the following…
- Trial name
- NCT06835387
- Testing
- Nanoliposomal irinotecan, Oxaliplatin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tiago Biachi de Castria
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
This study is to evaluate the safety and tolerability of of LT-010391 as monotherapy in participants with KRAS G12D mutant advanced solid tumors
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
- Trial name
- NCT07624214
- Testing
- LT-010391
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Neoplasms, Non-small-cell Lung Cancer
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or…
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT06285097
- Testing
- PF-07820435, Sasanlimab
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 9 people
- Sponsor
- Pfizer
Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the…
- Conditions
- Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma
- Trial name
- NCT02595424
- Testing
- Capecitabine, Carboplatin, Cisplatin
- Where
- 673 sites in United States
- Volunteers
- 67 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Solid Tumor, Adult, Triple Negative Breast Cancer
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT04282044
- Testing
- CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioEclipse Therapeutics
Breast Cancer, Colorectal Cancer
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00033384
- Testing
- CI-1040
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Advanced Solid Tumors
TT-702 in Patients With Advanced Solid Tumours.
This clinical trial is evaluating the drug candidate TT-702 in patients with advanced solid tumours. The main aims of the trial are to determine the maximum dose of TT-702 that can be given safely to patients alone and in…
- Trial name
- CURATE (NCT05272709)
- Testing
- TT-702, Anti-PD-1 and PD-L1 agent
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Cancer Research UK
Solid Tumor, Advanced Solid Tumor
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05737706
- Testing
- MRTX1133
- Where
- 14 sites in United States
- Volunteers
- 63 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced Cancer, Pancreatic Cancer
Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)
Determine Phase 2 dose of study drug
- Conditions
- Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer
- Trial name
- NivoPlus (NCT02423954)
- Testing
- Temsirolimus, Irinotecan, Irinotecan + capecitabine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Western Regional Medical Center
Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC)
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
- Conditions
- Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- FIT-001 (NCT06026410)
- Testing
- Darlifarnib, Cabozantinib, Adagrasib
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 300 people
- Sponsor
- Kura Oncology, Inc.
Solid Tumor, Adult, HCC - Hepatocellular Carcinoma
Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
INDP-D101 is a Phase 1/2, open-label, multi-center, dose escalation and expansion study evaluating the safety, tolerability and clinical activity of Decoy20 as monotherapy and in combination with tislelizumab in patients with…
- Conditions
- Solid Tumor, Adult, HCC - Hepatocellular Carcinoma, CRC (Colorectal Cancer), Pancreatic Adenocarcinoma
- Trial name
- NCT05651022
- Testing
- Decoy20, Tislelizumab
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Indaptus Therapeutics, Inc
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors
This is a first-in-human, Phase 1, open label, multicenter, multiple dose, dose escalation and dose expansion study intended to evaluate the safety, pharmacokinetic, pharmacodynamic, and potential clinical benefit of PF-07209960…
- Conditions
- Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04628780
- Testing
- PF-07209960
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in…
- Trial name
- NCT07094113
- Testing
- AMG 410, Pembrolizumab, Panitumumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Non-Small Cell Lung Cancer, Advanced Solid Tumors
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT05029882
- Testing
- ABBV-400, Trifluridine/Tipiracil, Bevacizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 520 people
- Sponsor
- AbbVie
Ampulla of Vater Adenocarcinoma, Small Intestinal Adenocarcinoma
Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma
This phase II trial studies how well bevacizumab given with capecitabine and oxaliplatin work in treating participants with small bowel or ampulla of Vater adenocarcinoma that has spread to other places in the body.
- Conditions
- Ampulla of Vater Adenocarcinoma, Small Intestinal Adenocarcinoma, Stage III Ampulla of Vater Cancer AJCC v8, Stage III Small Intestinal Adenocarcinoma AJCC v8
- Trial name
- NCT01208103
- Testing
- Bevacizumab, Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center